151 related articles for article (PubMed ID: 22809445)
1. Apolipoprotein A-V modulates multiple atherogenic mechanisms in a mouse model of disturbed clearance of triglyceride-rich lipoproteins.
Grosskopf I; Shaish A; Afek A; Shemesh S; Harats D; Kamari Y
Atherosclerosis; 2012 Sep; 224(1):75-83. PubMed ID: 22809445
[TBL] [Abstract][Full Text] [Related]
2. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
[TBL] [Abstract][Full Text] [Related]
3. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
[TBL] [Abstract][Full Text] [Related]
4. Effect of an oral astaxanthin prodrug (CDX-085) on lipoprotein levels and progression of atherosclerosis in LDLR(-/-) and ApoE(-/-) mice.
Ryu SK; King TJ; Fujioka K; Pattison J; Pashkow FJ; Tsimikas S
Atherosclerosis; 2012 May; 222(1):99-105. PubMed ID: 22406426
[TBL] [Abstract][Full Text] [Related]
5. [Expression profiles of lipid metabolism-related genes in liver of apoE(-/-)/LDLR(-/-) mice].
Du HQ; Yin M; Ye HY; Shang YJ; Dai XD; Jing W; Zhang L; Xiao N; Li JF; Pan J
Zhonghua Bing Li Xue Za Zhi; 2007 Nov; 36(11):751-5. PubMed ID: 18307880
[TBL] [Abstract][Full Text] [Related]
6. NOX1 deficiency in apolipoprotein E-knockout mice is associated with elevated plasma lipids and enhanced atherosclerosis.
Sobey CG; Judkins CP; Rivera J; Lewis CV; Diep H; Lee HW; Kemp-Harper BK; Broughton BR; Selemidis S; Gaspari TA; Samuel CS; Drummond GR
Free Radic Res; 2015 Feb; 49(2):186-98. PubMed ID: 25496431
[TBL] [Abstract][Full Text] [Related]
7. A 1,3-diacylglycerol-rich oil induces less atherosclerosis and lowers plasma cholesterol in diabetic apoE-deficient mice.
Fujii A; Allen TJ; Nestel PJ
Atherosclerosis; 2007 Jul; 193(1):55-61. PubMed ID: 16996521
[TBL] [Abstract][Full Text] [Related]
8. Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development.
Pan S; White TA; Witt TA; Chiriac A; Mueske CS; Simari RD
Circ Res; 2009 Sep; 105(7):713-20, 8 p following 720. PubMed ID: 19713537
[TBL] [Abstract][Full Text] [Related]
9. [Differential expressions of lipid metabolism related genes in the liver of young apoE knockout mice].
Ye HY; Yin M; Shang YJ; Dai XD; Zhang SQ; Jing W; Du HQ; Zhang L; Pan J
Sheng Li Xue Bao; 2008 Feb; 60(1):51-8. PubMed ID: 18288358
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein A-I protection against atherosclerosis is dependent on genetic background.
Sontag TJ; Krishack PA; Lukens JR; Bhanvadia CV; Getz GS; Reardon CA
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):262-9. PubMed ID: 24334873
[TBL] [Abstract][Full Text] [Related]
11. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice.
Zhang WJ; Bird KE; McMillen TS; LeBoeuf RC; Hagen TM; Frei B
Circulation; 2008 Jan; 117(3):421-8. PubMed ID: 18158360
[TBL] [Abstract][Full Text] [Related]
12. Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice.
Koulis C; Chen YC; Hausding C; Ahrens I; Kyaw TS; Tay C; Allen T; Jandeleit-Dahm K; Sweet MJ; Akira S; Bobik A; Peter K; Agrotis A
Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):516-25. PubMed ID: 24436372
[TBL] [Abstract][Full Text] [Related]
13. Human apolipoprotein A-II associates with triglyceride-rich lipoproteins in plasma and impairs their catabolism.
Dugué-Pujol S; Rousset X; Pastier D; Quang NT; Pautre V; Chambaz J; Chabert M; Kalopissis AD
J Lipid Res; 2006 Dec; 47(12):2631-9. PubMed ID: 16990646
[TBL] [Abstract][Full Text] [Related]
14. C3H apoE(-/-) mice have less atherosclerosis than C57BL apoE(-/-) mice despite having a more atherogenic serum lipid profile.
Grimsditch DC; Penfold S; Latcham J; Vidgeon-Hart M; Groot PH; Benson GM
Atherosclerosis; 2000 Aug; 151(2):389-97. PubMed ID: 10924715
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels.
Raffai RL; Loeb SM; Weisgraber KH
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):436-41. PubMed ID: 15591220
[TBL] [Abstract][Full Text] [Related]
16. Impaired phosphatidylcholine biosynthesis reduces atherosclerosis and prevents lipotoxic cardiac dysfunction in ApoE-/- Mice.
Cole LK; Dolinsky VW; Dyck JR; Vance DE
Circ Res; 2011 Mar; 108(6):686-94. PubMed ID: 21273556
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of recombinant high density lipoprotein with apolipoprotein A-I and apolipoprotein A-V.
Zhang X; Chen B
Biol Chem; 2011 May; 392(5):423-9. PubMed ID: 21476871
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice.
Atkinson RD; Coenen KR; Plummer MR; Gruen ML; Hasty AH
Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E284-90. PubMed ID: 18029445
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production.
Post SM; Groenendijk M; Solaas K; Rensen PC; Princen HM
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):768-74. PubMed ID: 14962946
[TBL] [Abstract][Full Text] [Related]
20. Hydrogen sulfide regulates vascular endoplasmic reticulum stress in apolipoprotein E knockout mice.
Chen ZF; Zhao B; Tang XY; Li W; Zhu LL; Tang CS; DU JB; Jin HF
Chin Med J (Engl); 2011 Nov; 124(21):3460-7. PubMed ID: 22340159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
